Barclays PLC Has $25.77 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Barclays PLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 20.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 130,826 shares of the medical research company's stock after selling 34,379 shares during the period. Barclays PLC owned about 0.26% of Charles River Laboratories International worth $25,769,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Oregon Public Employees Retirement Fund boosted its stake in Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock valued at $914,000 after acquiring an additional 45 shares during the period. Empirical Finance LLC boosted its position in Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after purchasing an additional 53 shares during the period. American Trust grew its stake in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after buying an additional 54 shares during the last quarter. Tortoise Investment Management LLC increased its position in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after buying an additional 57 shares during the period. Finally, OLD National Bancorp IN lifted its stake in Charles River Laboratories International by 3.1% in the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock valued at $392,000 after buying an additional 59 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $3.81 during trading on Friday, hitting $190.46. The company had a trading volume of 547,747 shares, compared to its average volume of 616,658. The business's 50-day moving average is $194.35 and its 200 day moving average is $203.02. The company has a market cap of $9.74 billion, a P/E ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.72 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and dropped their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. UBS Group raised their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday. StockNews.com cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, TD Cowen boosted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $214.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).